Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients

Universitas Sebelas Maret

Status and phase: Completed; Phase 2; Phase 1

Conditions: COVID-19

Treatments: Drug: N-acetyl cysteine

Study type: Interventional

Funder types: Other

Identifiers

NCT05658549

NAP02

Details and patient eligibility

About

This research is a study that compares the administration of N-acetylcysteine at various doses with the outcomes of COVID-19 patients, namely the neutrophil-to-lymphocyte ratio and length of stay.

Full description

This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group K1 received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.

Enrollment: 120 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• moderate or severe grade confirmed COVID-19 (patients with symptoms and radiological examination showing pneumonia with or without signs of severe pneumonia: SpO2<90%, respiratory rate>30x/min, and severe respiratory distress) who were admitted to UNS Hospital and age 18-60 years old

Exclusion criteria

• patients who died during the treatment period

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Quadruple Blind

---

120 participants in 4 patient groups, including a placebo group

N-acetylcysteine injection 1200 mg

Experimental group

Description:

N-acetylcysteine injection 1200 mg per day

Treatment:

Drug: N-acetyl cysteine

N-acetylcysteine pill 1200 mg

Experimental group

Description:

N-acetylcysteine pill 1200 mg orally per day

Treatment:

Drug: N-acetyl cysteine

N-acetylcysteine pills 600 mg per day

Experimental group

Description:

N-acetylcysteine pills 600 mg per day orally

Treatment:

Drug: N-acetyl cysteine

placebo

Placebo Comparator group

Description:

Capsule with shape and appearance similar to N-acetylcysteine

Treatment:

Drug: N-acetyl cysteine